

NR 546
 Week 6 Addiction Medication Table
 8/23

Drug Name	Indication Neurotransmitter(s) Affected Target Symptoms	Half-life (T1/2), Metabolism (CYP 450 enzyme)	Notable Side Effects (link to NT or affected brain circuit)	Initial Specifi consid pregn
Buprenorphine (Subutex)	Indication: Treatment of opioid addiction and opioid dependence Target Symptoms: Pain relief, reduced cravings, and improved quality of life. Affected Neurotransmitters: Activates opioid receptors, primarily the mu-opioid receptor.	<i>Subutex</i> half-life 38 hours, Cytochrome P450 3A4/3A5-mediated N-dealkylation	Activates opioid receptors, primarily the mu-opioid receptor, which can lead to constipation, nausea, drowsiness, dizziness, itching, and vomiting.	- use -safe breast
Buprenorphine/Naloxone (Suboxone, Zubsolv, [Bunavail-no longer available as of March 2020])	Indication: Treatment of opioid addiction and opioid dependence. Target Symptoms: Pain relief, reduced cravings, and improved quality of life. Affected Neurotransmitters: Activates opioid receptors, primarily the mu-opioid receptor.	<i>Suboxone</i> , Zubsolv, 24 to 42 hours <i>Bunavail</i> , 16.4 to 27.5 hours. Cytochrome P450 3A4 (CYP3A4) enzyme	Activates opioid receptors, primarily the mu-opioid receptor, which can lead to constipation, nausea, drowsiness, dizziness, itching, and vomiting.	-use f -safe breast